Holen Sie sich die Stockscreener-App
10.45
0.48%
-0.05
Schlusskurs vom Vortag:
$10.50
Offen:
$10.51
24-Stunden-Volumen:
810.04K
Relative Volume:
1.12
Marktkapitalisierung:
$1.40B
Einnahmen:
$58.49M
Nettoeinkommen (Verlust:
$-105.04M
KGV:
-8.0403
EPS:
-1.2997
Netto-Cashflow:
$-13.78M
1W Leistung:
+2.25%
1M Leistung:
+5.66%
6M Leistung:
+86.94%
1J Leistung:
+40.84%
1-Tages-Spanne:
$10.36
$10.90
1-Wochen-Bereich:
$9.89
$10.90
52-Wochen-Spanne:
$3.30
$12.41
Immatics N V Stock (IMTX) Company Profile
Vergleichen Sie IMTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
10.45 | 1.41B | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-05-28 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2020-11-20 | Eingeleitet | BofA Securities | Buy |
| 2020-09-22 | Eingeleitet | Goldman | Buy |
| 2020-07-27 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-24 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immatics N V Aktie (IMTX) Neueste Nachrichten
Immatics (NASDAQ:IMTX) Upgraded at Wall Street Zen - Defense World
Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy? - Defense World
Aug Analyst Calls: Why Immatics NV Equity Warrant stock could be next big winnerWeekly Profit Report & High Accuracy Trade Signal Alerts - moha.gov.vn
Immatics (NASDAQ:IMTX) Trading Up 3.9%Time to Buy? - MarketBeat
Analysis Recap: Why Immatics N.V. stock is rated strong buy2025 Market Trends & Step-by-Step Trade Execution Guides - moha.gov.vn
Aug Final Week: Why Immatics NV stock remains on buy lists2025 Risk Factors & Long Hold Capital Preservation Tips - moha.gov.vn
Retail Surge: Is Immatics NV stock a top pick in earnings seasonTrade Performance Summary & Weekly Stock Breakout Alerts - moha.gov.vn
Aug Drivers: Is Immatics NV stock a top pick in earnings seasonQuarterly Profit Summary & Daily Growth Stock Tips - moha.gov.vn
(IMTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Immatics: PRAME Leader's Transition To Commercial Reality - Seeking Alpha
Why Immatics N.V. Equity Warrant stock appeals to dividend seekersTrend Reversal & Smart Allocation Stock Reports - Улправда
Is Immatics N.V. (4A3) stock a top dividend aristocrat candidate2025 Short Interest & Weekly Top Stock Performers List - Улправда
Aug Final Week: Can Immatics N.V. stock attract ESG capital inflowsWeekly Trade Review & Community Verified Swing Trade Signals - Улправда
Why hedge funds are buying Immatics N.V. stock2025 Buyback Activity & Reliable Entry Point Trade Alerts - Улправда
Why Immatics N.V. stock is rated strong buyJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Mizuho Securities Sticks to Their Buy Rating for Immatics (IMTX) - The Globe and Mail
Why Immatics N.V. stock is considered a top pickTrade Exit Report & Community Verified Watchlist Alerts - Улправда
Why Immatics N.V. (4A3) stock trades below fair valueJuly 2025 Price Swings & AI Optimized Trading Strategy Guides - Улправда
How Immatics N.V. Equity Warrant stock performs in rate cut cyclesM&A Rumor & Risk Adjusted Buy and Sell Alerts - DonanımHaber
How Immatics N.V. Equity Warrant stock reacts to Fed rate cutsInsider Selling & Comprehensive Market Scan Insights - DonanımHaber
How buybacks impact Immatics N.V. stock valueShort Setup & High Accuracy Trade Alerts - DonanımHaber
Can Immatics N.V. (4A3) stock test all time highsJuly 2025 Levels & Low Risk Investment Opportunities - DonanımHaber
How Immatics N.V. Equity Warrant stock compares to market leadersJuly 2025 Short Interest & Growth Oriented Trading Recommendations - DonanımHaber
Is Immatics N.V. stock a top pick in earnings seasonMarket Risk Report & Entry Point Strategy Guides - DonanımHaber
Bearish Setup: Why Immatics N.V. Equity Warrant stock could see breakout soonMarket Performance Summary & Capital Efficiency Focused Strategies - Улправда
Will Immatics N.V. Equity Warrant stock continue upward momentumJuly 2025 Earnings & Intraday High Probability Setup Alerts - DonanımHaber
Why Immatics N.V. Equity Warrant stock could see breakout soonWeekly Trade Review & Precise Trade Entry Recommendations - Улправда
Is Immatics N.V. Equity Warrant stock a buy for dividend growthIndex Update & Reliable Intraday Trade Alerts - Улправда
New Highs: Can Immatics N.V. stock attract ESG capital inflowsWeekly Stock Recap & Verified Swing Trading Watchlists - Улправда
Immatics appoints industry veteran as CFO - MSN
How Immatics’ US$125 Million Follow-on Equity Raise At Immatics (IMTX) Has Changed Its Investment Story - simplywall.st
Immatics completes $116.5 million share offering to boost R&D - MSN
(IMTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Immatics N.V. (NASDAQ:IMTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Immatics (IMTX) Updates on Promising IMA203CD8 Cell Therapy Tria - GuruFocus
Immatics presents IMA203CD8 PRAME cell therapy data at ESMO-IO Congress - TipRanks
Immatics Reveals Promising Results from IMA203CD8 Phase 1a Trial - TipRanks
Immatics Announces Promising Phase 1a Dose Escalation Results for IMA203CD8, a Second-Generation PRAME Cell Therapy for Advanced Solid Tumors - Quiver Quantitative
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - FinanzNachrichten.de
Is Immatics NV a good long term investmentMorning Star Patterns & Breakthrough Stock Performance - earlytimes.in
A look into Immatics N.V (IMTX)’s deeper side - setenews.com
Immatics Completes $116.5 Million Share Offering to Boost R&D - The Globe and Mail
Immatics announces offering of 12.5M ordinary shares - MSN
How Investors Are Reacting To Immatics (IMTX) $125 Million Follow-On Equity Offering - simplywall.st
Finance Watch: Biotech Investors Take FDA Turmoil In Stride - Citeline News & Insights
Immatics (NASDAQ:IMTX) Trading Up 8.9%Time to Buy? - MarketBeat
Immatics Down Nearly 15%, on Pace for Largest Percent Decrease Since October 2024 -- Data Talk - 富途牛牛
Immatics announces $125 million underwritten offering - marketscreener.com
Immatics Announces $125 Million Underwritten Offering - TradingView — Track All Markets
Perhaps timely catching Immatics N.V (IMTX) would be a good idea - Setenews
Immatics Plans $125 Million Stock Offering - marketscreener.com
Finanzdaten der Immatics N V-Aktie (IMTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):